Drugs / pegylated interferon alfa 2
pegylated interferon alfa 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02661477 | May 2016 → May 2018 | viral respiratory tract infection | Turku University Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated interferon alfa 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661477 ↗ |
| Known as | Pegasys | “subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).” NCT02661477 ↗ |
| Known as | pIFNα2a | “subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).” NCT02661477 ↗ |
| Route | Subcutaneous | “receive subcutaneous pIFNα2a” NCT02661477 ↗ |